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Abstract
Polyhistidine triad protein D (PhtD) has been described as a promising vaccine candidate for use against Streptococcus
pneumoniae, but there has been a lack of examination of its structure and of which region(s) of the protein are targeted by
protective immune responses. In this study, we purified recombinant truncated derivatives of PhtD and examined their
secondary structural composition, as well as their capacity to bind antibodies from polyclonal murine serum generated
against the full length protein. This allowed the identification of a particularly immunogenic fragment of PhtD, which was
also purified and characterised. The truncated derivatives were tested as vaccine antigens in mouse models of
pneumococcal sepsis and colonisation, using alum and E. coli heat labile toxin B subunit respectively as adjuvants. These
experiments revealed that whilst the immunogenic region identified may be a promising candidate to protect against
sepsis, the full length PhtD was ineffective at conferring significant protective immunity. These results are significant for the
potential for PhtD to be used in novel vaccines, which are currently being tested in clinical trials.
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Introduction
Streptococcus pneumoniae is a human pathogen able to cause a wide
spectrum of diseases, such as pneumonia, sepsis, meningitis and
otitis media, and these result in significant global morbidity and
mortality [1]. The most recently licensed vaccines against
pneumococcal disease are made up of a protein-capsular
polysaccharide conjugates. However, these have serious limitations
in terms of cost, serotype coverage and increases in the incidence
of disease caused by non-vaccine serotypes post introduction [2–
4].
As an alternative strategy, efforts have been made to identify
and characterise pneumococcal protein antigens that can elicit
protective immunity and are conserved amongst serotypes. To
date, a large number of candidates have been found using a variety
of strategies [5–9]. One such family of proteins are the
polyhistidine triad (Pht) family [10], which has four members
(PhtA, PhtB, PhtD and PhtE) in S. pneumoniae. These surface-
exposed antigens are characterised by the presence of five to six
histidine triad (HxxHxH) motifs and are highly conserved amongst
pneumococcal strains [11,12]. All four members have been shown
to elicit protective immunity in mouse models of pneumococcal
disease against a number of pneumococcal strains ([11,13–16];
summarized in [10]), although one study reported PhtB and PhtE
to be less promising candidates in terms of protection elicited
against sepsis compared to pneumolysin toxoid PdB, PspA and
PspC, where alum was used as the adjuvant [9]. Immunisation
with PhtD with AS02 adjuvant leading to protective immunity in
rhesus macaques has also been demonstrated [17], and passive
transfer of anti-PhtD antibodies purified from naturally exposed
humans was shown to protect mice against lethal challenge [16].
More recently, successful phase I clinical trials using PhtD and
alum in vaccine formulations have been reported [18,19]. The Pht
proteins are therefore considered highly promising vaccine
candidates.
Attention has focussed specifically on PhtD, due to it showing
greater conservation amongst strains tested [12] and superior
protection elicited in a nasopharyngeal colonisation model with E.
coli labile toxin as the adjuvant [16] as compared to the other Pht
proteins. At 110 kDa, PhtD is a relatively large surface protein,
and is thought to be anchored to the surface via attachment to the
cell wall [20]. Indeed, we have recently shown that a three amino
acid region near the N-terminus of PhtD (Q27-H28-R29) is
essential for surface attachment [21]. It therefore seems highly
likely that certain regions of PhtD, and indeed the other Pht
proteins, will show a varying degree of exposure on the bacterial
surface due to the orientation and topology of the protein and the
presence of the capsule layer hindering access to deeper regions.
Flow cytometry experiments have indicated that regions near the
C-termini of the Pht proteins are more exposed than regions near
their N-termini [11,14]. Additionally, immunisation with a fusion
protein consisting of the C-termini of PhtB and PhtE with Quil A
adjuvant was found to elicit an improved antibody response
compared to when the individual truncated protein components
were used to immunise mice [14]. The fusion protein was
protective in a lethal pneumonia model and passive transfer of
antibodies raised against it were protective in a sepsis model [14].
However, these analyses were far from comprehensive and were
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not performed for PhtD, the most promising vaccine candidate of
the family.
In order to increase understanding of the topology of PhtD as
well as the contribution to vaccine efficacy of different regions the




Five to six week old female CD1 mice were obtained from the
Laboratory Animal Services breeding facility at the University of
Adelaide. Ethics approval for all experiments was granted by the
Animal Ethics Committee of the University of Adelaide (project
number S-2013-053); experiments were conducted in compliance
with the Australian Code of Practice for the Care and Use of
Animals for Scientific Purposes (7th edition, 2004) and the South
Australian Animal Welfare Act 1985.
Cloning, expression and purification of truncated
derivatives
Primers with HindIII and BamHI restriction sites incorporated
were designed to amplify truncated derivatives of phtD, which were
ligated into the pQE-30, -31 and -32 vectors [Qiagen, VIC,
Australia] using T4 DNA ligase according to the manufacturer’s
instructions [New England Biolabs, Mass, USA]. The resultant
His6-tagged constructs were used to transform E. coli BL21 (DE3)
lpxM2 [22]. Expression and purification via metal affinity
chromatography were performed as described previously [8].
Generation of polyclonal antisera
Purified protein antigens were mixed with ImjectH Alum
[Thermo Scientific, VIC, Australia] and PBS for 30 min at room
temperature (RT). Three mice were immunised intraperitoneally
on day 0, 14 and 28. Each dose contained 10 mg of protein and
100 mg alum. Mice were euthanised on day 35 and blood was
collected from the posterior vena cava. The blood was allowed to
coagulate at RT for 30 min before collection of serum by
centrifugation. Equal volumes of serum from each of the three
mice were pooled.
ELISA
Proteins were diluted to 5 mg/ml in TSA buffer (132 mM NaCl,
25 mM Tris-HCl, 0.05% w/v NaN3, pH 7.5) and allowed to
adsorb onto the wells of Nunc MaxiSorp 96 well trays [Thermo
Fisher Scientific] overnight at 4uC. Blocking was performed using
1% w/v bovine serum albumin (BSA) dissolved in PBS for 2 h at
37uC. Serial dilutions of pooled mouse serum were subsequently
allowed to bind overnight at 4uC, followed by rabbit anti-mouse
Figure 1. Coils prediction server output for PhtD. The Coils server (http://embnet.vital-it.ch/software/COILS_form.html) was used to compare
the amino acid sequence of PhtD to a database of proteins known to form coiled-coils to yield a prediction of which regions (if any) will fold in this
conformation. The x-axis represents the position in the protein by amino acid number (starting at the N-terminus) and the y-axis shows how strongly
that region is predicted to form a coiled coil. ‘Window’ refers to the width of the amino acid ‘window’ that is scanned at one time.
doi:10.1371/journal.pone.0078916.g001
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alkaline phosphatase conjugated secondary antibody [Bio-Rad,
NSW, Australia] diluted 1:3000 v/v in PBS and incubated for 2 h
at RT. Lastly, 4-nitrophenyl phosphate disodium salt hexahydrate
[Sigma, NSW, Australia] was diluted in substrate buffer (10% v/v
diethanolamine, 1 M MgCl2, 0.02% w/v NaN3, pH 9.8) to
500 mg/ml and incubated at RT in the tray until a yellow colour
developed, at which point trays were read at 405 nm using a
Spectramax M2 microplate reader [Molecular Devices, California,
USA]. Trays were washed five times with PBS between each step.
Titres (dilution of mouse serum resulting in half-maximal response)
were determined using Prism [GraphPad Software, California,
USA].
Circular dichroism spectroscopy
Proteins were diluted to 0.15 mg/ml in 10 mM sodium
phosphate buffer at pH 7.4. Absorbance in the ultraviolet
spectrum was measured using a J-815 Spectropolarimeter [Jasco
Analytical Instruments, Maryland, USA] according to the
manufacturer’s instructions. Calculations of proportions of sec-
ondary structural elements were performed using the DichroWeb
online analysis tool (available at http://dichroweb.cryst.bbk.ac.
uk/html/home.shtml) using the CDSSTR programme.
Figure 2. Truncated forms of PhtD used in this study. Proteins are shown with known or predicted domains annotated. The N termini are to
the left.
doi:10.1371/journal.pone.0078916.g002
Table 1. List of starting and ending amino acids of PhtD
truncated derivatives.
Protein Starting amino acid Last amino acid
PhtD C1 Cys20 Phe655
PhtD C2 Cys20 Ser445
PhtD C3 Cys20 Asn247
PhtD N1 Pro248 Gln853
PhtD N2 Asp446 Gln853
PhtD N3 Asp656 Gln853
All purified protein derivatives omit the putative N-terminal signal peptide
(amino acids 1 - 19).
doi:10.1371/journal.pone.0078916.t001
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Sepsis model experiments
Mice were immunised as described above for generation of
polyclonal antisera. For the D39 (serotype 2; NCTC 7466)
experiment, equal quantities of each protein by mass were used in
the immunisations; for the P9 (a serotype 6A strain) experiment,
equimolar amounts were used. On day 35, approximately 100 ml
of blood was collected by submandibular bleeding. This was
allowed to coagulate at RT for 30 min before collection of serum
by centrifugation. Equal volumes of serum from each mouse were
pooled for antibody titre analysis. On day 42, mice were injected
intraperitoneally with pneumococci of strain D39 (56104 CFU
per mouse) or P9 (26105 CFU per mouse) and survival times were
recorded.
Colonisation model experiment
Mice were immunised intranasally with 10 ml containing 10 mg
of protein and 0.2 mg E. coli heat labile toxin B subunit (gift from
Tom Duthy, University of Adelaide) on days 0, 14 and 28. On day
42, mice were anaesthetised by intraperitoneal injection of
pentobarbital sodium [Nembutal; Rhone-Merieux, QLD, Austra-
lia] at a dose of 66 mg/g body weight, then given 6.56106 CFU of
strain D39 intranasally by pipetting onto the nares. After 96 hours,
mice were euthanised by CO2 asphyxiation and pneumococci
from the nasopharynx were enumerated as described previously
[23].
Flow cytometry
Bacteria were grown in Todd-Hewitt broth supplemented with
1% yeast extract to mod-log phase, then were incubated with
murine antisera serum for 1 h at 37uC followed by Alexa FluorH
488 rabbit anti-mouse IgG (H+L) [Life Technologies] for 30 min
at 4uC. Three washes with 1 ml PBS were performed between
each step and all antibodies were diluted 1:100 v/v in PBS.
Fluorescence measurements from 10,000 events were collected
using a BD FACSCanto flow cytometer [BD Biosciences, NSW,
Australia]. Data were analysed using the software package FlowJo
[Tree Star, Oregon, USA].
Statistics
Survival times and CFU counts of mice immunised with
pneumococcal antigens were compared to those of the adjuvant-
only negative control groups using one-tailed Mann-Whitney tests.
Results
Design and purification of truncated derivatives
Primers were designed to amplify truncated derivatives of PhtD
lacking approximately 200 amino acids and multiples thereof from
both the C- and N-terminus of the protein. The first 57
nucleotides, which are predicted to encode the protein’s signal
peptide, were excluded from all constructs such that this region
was not present in the expressed proteins. In order to minimise
potential disruption to overall protein structure, the exact positions
of the truncations were designed to fall between coiled-coil
domains as predicted by the Coils server [24] (see Figure 1). The
truncated derivatives that were constructed are represented in
Figure 2 and the amino acids included are listed in Table 1.
The protein products of the cloned genes were expressed in E.
coli and purified by metal affinity chromatography. All were
judged to be .90% pure by Coomassie staining following SDS-
PAGE analysis (see Figure 3).
Antibody binding regions of PhtD
A polyclonal murine antiserum was generated against the full
length PhtD protein and ELISAs were performed to examine the
extent of binding of the antiserum to the truncated derivative
proteins. Results are shown in Figure 4A (truncations from the C
terminus) and 4B (truncations from the N terminus). The
truncated derivatives can be grouped based on the ability of
antibodies in the antisera to bind to them relative to the full length
protein: C1, N1 and N2 show high binding whilst C2, C3 and N3
show markedly lower binding. Interestingly, the region of PhtD
between Asp446 and Phe655 is common to C1, N1 and N2 (the
high antibody binders) but is lacking in C2, C3 and N3 (the low
antibody binders), consistent with this region being highly
immunogenic.
We therefore cloned, expressed and purified the region
consisting of Asp446 to Phe655 (PhtD adjunct) and tested its
antibody binding as for the truncated derivatives above (figure 4C).
This protein showed a similar level of antibody binding as the full
length PhtD, consistent with this region being immunogenic.
Measurement of protein secondary structural elements
by circular dichroism spectroscopy
Circular dichroism (CD) spectroscopy was used to examine the
truncated derivatives of PhtD and the full length protein. Data on
absorbance in the ultraviolet spectrum were collected and analysed
using the CDSSTR algorithm via DichroWeb [25–27]. This was
performed to provide information on the structure of PhtD, as well
as to determine whether the truncated derivatives were disordered
in their secondary structural elements, or whether they were folded
in a manner representative of the full length protein. Results
showing the proportions of each protein predicted to be in alpha-
helical, beta-strand, beta-turn or unordered conformations are
shown in Table 2. All of the truncated derivatives were found to
contain similar proportions in an unordered conformation as the
full length protein, consistent with the protein fragments assuming
a correctly folded structure. In addition, the results reveal that
PhtD has a high proportion of a-helix in the C-terminal half of the
protein, since PhtD N1, N2 and the PhtD adjunct contained high
proportions of this secondary structural element.
Figure 3. SDS-PAGE analysis of purified truncated derivatives
of PhtD. Truncated derivatives of PhtD were analysed by SDS-PAGE
using a 12% acrylamide gel and subsequently stained using Coomassie
R250. 1 mg of each protein was used. The identity of the protein is
indicated above each lane (FL; full length).
doi:10.1371/journal.pone.0078916.g003
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The PhtD adjunct protein showed statistically significant
protection against sepsis caused by strain D39
Given that the PhtD adjunct protein bound a high amount of
antibody from the polyclonal antiserum, it was of interest to
determine whether it could induce protective immunity against
systemic pneumococcal disease. Groups of 12 mice were
immunised with the indicated proteins and challenged via
intraperitoneal injection with 56104 wild-type pneumococci of
strain D39, and survival times were measured (see Figure 5). Only
the groups given the PhtD adjunct protein, or the combination of
PdT (a genetic toxoid derivative of pneumolysin), PspA and PspC,
showed significant increases in median survival time relative to
that of the alum control group (P,0.05 for the PhtD adjunct and
P,0.0001 for the combination of PdT, PspA and PspC). Neither
the full length PhtD protein nor a combination of PhtA, PhtB,
PhtD and PhtD conferred significant protection compared to wild-
type. Titres of antibodies specific for each antigen in pooled sera
from each group of mice were measured by ELISA and the results
are shown in Table 3.
PhtD truncated antigens do not induce protective
immunity against colonisation by strain D39
To further investigate the protective roles of different regions of
PhtD, protection against colonisation by S. pneumoniae was
examined by immunising groups of eight mice via the intranasal
route with full length PhtD and truncated derivatives using E. coli
labile toxin B subunit (LTB) as adjuvant. 10 mg of PhtD was given
per dose; amounts of truncated derivatives of PhtD were adjusted
such that equimolar quantities of these antigens to that of full-
length PhtD were given. Control groups were immunised with
adjuvant alone (negative control) or with adjuvant and PspA
(positive control). Mice were subsequently challenged with strain
D39 intranasally under anaesthesia. After 96 hours, mice were
euthanized and numbers of pneumococci in the nasopharynx were
enumerated. This model was chosen since immunisation with
PhtD has previously been shown to significantly reduce pneumo-
coccal colonisation under similar experimental conditions [16].
Results are shown in Figure 6. A small number of mice died from
invasive pneumococcal disease before the 96 hours had elapsed;
results from these mice were excluded. Whilst modest differences
in median CFU recovered can be seen between groups, statistical
analysis revealed that none of the groups were significantly
different from the adjuvant alone negative control group. This
includes the PhtD and PspA positive control groups, which was
unexpected since these antigens have previously been shown to
confer protective immunity in this model [16].
PhtD does not confer protective immunity against sepsis
caused by strain P9
To test the effectiveness of immunisation with truncated
derivatives of PhtD against disease caused by a different strain
from D39, we next examined the clinically relevant serotype 6A
strain P9 (recently isolated as part of the Program for Appropriate
Technology in Health [PATH] pneumococcal vaccines project).
The presence and immunological cross-reactivity of Pht proteins
in this strain with Pht proteins of D39 was checked by Western
blotting using whole-cell lysates of wild-type P9 and D39, as well as
of a D39 DphtABDE mutant, with anti-PhtD or anti-PhtABDE
(from animals immunised with a combination of all four Pht
proteins) polyclonal murine sera. As shown in Figure 7A, there
were only small differences in the presence or reactivity of bands
corresponding to Pht proteins between D39 and P9, implying that
murine antibodies generated by immunisation with Pht proteins
(which were cloned from D39) were likely to be able to bind P9 in
the sepsis model. A band at around 80 kDa was detected in both
Western blots; it is not clear whether this represents PhtA (which
has a predicted molecular weight of approximately 92 kDa) or a
partly degraded form of PhtD.
To examine the surface exposure of Pht proteins, and in
particular of the different regions of PhtD, the extent of binding of
antisera generated against PhtD or truncated derivatives to wild-
type D39 or P9 was measured using flow cytometry (Figure 7B and
7C). This showed that the anti-PhtD and anti-PhtABDE sera
bound more readily to P9 than to D39, suggesting that there was
greater expression and/or exposure of PhtD on the surface of the
Figure 4. Antibody binding capacity of truncated derivatives of PhtD. ELISA was used to examine binding of anti-PhtD serum to PhtD and
truncated derivatives. PdB is an unrelated negative control protein (genetic toxoid derivative of pneumolysin [34]) to which no binding is expected. A:
proteins truncated from the C terminus. B: proteins truncated from the N terminus. C: PhtD adjunct protein.
doi:10.1371/journal.pone.0078916.g004
Table 2. Circular dichroism spectroscopy analysis of PhtD and
truncated derivatives.
Protein a-helix b-strand b-turn Unordered
PhtD 0.36 0.18 0.18 0.28
PhtD C1 0.25 0.26 0.20 0.30
PhtD C2 0.20 0.26 0.21 0.33
PhtD C3 0.16 0.29 0.21 0.34
PhtD N1 0.49 0.09 0.17 0.25
PhtD N2 0.56 0.07 0.14 0.23
PhtD N3 0.44 0.11 0.20 0.26
PhtD Adjunct 0.51 0.18 0.13 0.18
Results are shown as proportions of each protein predicted to be folded in each
of the indicated secondary structural conformations, or predicted to be
unordered.
doi:10.1371/journal.pone.0078916.t002
Table 3. Antibody titres of pooled sera from immunised mice
before challenge with D39.
Mouse Group Antigen Titre
PhtD PhtD 10,000





PdT + PspA + PspC PdT 8,800
PdT + PspA + PspC PspA 3,800
PdT + PspA + PspC PspC 5,900
Antibody titres were measured via ELISA. Titre was defined as the dilution of
mouse serum giving half-maximal absorbance, and was rounded to two
significant figures.
doi:10.1371/journal.pone.0078916.t003
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Figure 5. Survival times of mice challenged with D39 after immunisation with the indicated antigens. Median survival times are
indicated by horizontal lines. Significant differences from the alum only control group are indicated where present (*, P,0.05; ****, P,0.0001).
doi:10.1371/journal.pone.0078916.g005
Figure 6. CFU of pneumococci recovered from the nasopharynges of vaccinated mice. After three immunisations with the indicated
antigens, mice were challenged intranasally with wild-type D39 pneumococci. After 96 hours, pneumococci from the nasopharynx were enumerated.
Median CFU recovered is indicated by the solid lines; the dashed line indicates the limit of detection.
doi:10.1371/journal.pone.0078916.g006
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former strain, which could translate into more effective PhtD
antibody-mediated immunity. Both strains showed similar trends
in the relative amounts of binding observed for the antisera
generated against the truncated derivatives. The data also indicate
that the C terminus of PhtD is more exposed than the N terminus,
in line with previous observations, and that the PhtD adjunct
region is accessible to exogenous antibody.
Lastly, the ability of PhtD and the truncated derivatives to
induce protective immunity against sepsis caused by P9 was tested
in a mouse model. PdT was used as a positive control immunogen,
and combinations of PhtD and PdT or the PhtD adjunct and PdT
Figure 7. Presence and exposure of Pht proteins in strain P9 compared to D39. A: Western blotting using pneumococcal cell lysates with
anti-PhtD (left) or anti-PhtABDE (right) polyclonal sera. Mobilities of molecular size markers are indicated. B and C: detection of PhtD on the surface of
D39 (B) and P9 (C) by flow cytometry using antisera generated against PhtD truncated derivatives. NMS, normal mouse serum (negative control).
Median fluorescence intensities for 10,000 events are displayed.
doi:10.1371/journal.pone.0078916.g007
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were also tested to determine whether these antigens could confer
additive or synergistic protection. Survival times of the mice were
measured and are shown in Figure 8. Whilst marginal increases in
median survival time were observed for a number of groups, only
groups immunised with PhtD N1, PdT, PhtD + PdT or PhtD
adjunct + PdT showed statistically significant differences com-
pared to that of the alum group. Thus, immunisation with full
length PhtD did not confer significant protective immunity.
Furthermore, PhtD also did not increase the survival time of
mice immunised with PhtD + PdT, compared with PdT alone.
The same was true of the PhtD adjunct in combination with PdT.
Antibody titre measurements (shown in Table 4) from pre-
challenge pooled sera demonstrated that, despite the lack of
protection, strong IgG responses had been induced, especially for
the PhtD adjunct. It was therefore concluded that PhtD is a
suboptimal candidate for a protein vaccine component in this
model of pneumococcal disease, relative to PdT.
Discussion
PhtD is an important vaccine candidate for use against the
pneumococcus and phase II clinical trials are currently underway
to assess its potential. In this work, we have explored the structure
and immunogenicity of various regions of the protein, as well as its
ability to confer protective immunity against both colonisation and
invasive disease caused by the pneumococcus.
Secondary structural elements and immunogenicity of
truncated proteins
The circular dichroism spectroscopy data showed that a large
proportion of the C-terminal half of PhtD is folded into an alpha
helical conformation. This is in concordance with the prediction
that coiled-coils, which are composed of alpha helices, are found in
this region (Figure 1). The PhtD adjunct protein (Asp446 to
Figure 8. Survival times of mice challenged with P9 after immunisation with the indicated antigens. Median survival times are indicated
by horizontal lines. Significant differences from the alum only control group are indicated where present (*, P,0.05; **, P,0.01).
doi:10.1371/journal.pone.0078916.g008
Table 4. Antibody titres of pooled sera from immunised mice
before challenge with P9.
Mouse Group Antigen Titre
PhtD PhtD 22,000
PhtD + PdT PhtD 8,400
PhtD C1 PhtD C1 23,000
PhtD C2 PhtD C2 10,000
PhtD C3 PhtD C3 4,700
PhtD N1 PhtD N1 9,700
PhtD N2 PhtD N2 8,600
PhtD N3 PhtD N3 6,400
PhtD Adjunct PhtD Adjunct 110,000
PhtD Adjunct + PdT PhtD Adjunct 110,000
PdT PdT 9,300
PhtD + PdT PdT 10,000
PhtD Adjunct + PdT PdT 8,900
Antibody titres were measured via ELISA. Titre was defined as the dilution of
mouse serum giving half-maximal absorbance, and was rounded to two
significant figures.
doi:10.1371/journal.pone.0078916.t004
Vaccination against Streptococcus pneumoniae
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Phe655) was found to be highly immunogenic and to contain a
large proportion of alpha helix, potentially in a coiled coil
arrangement. It is encouraging that such a region should be so
immunogenic, since it is also likely that an elongated structure
such as a coiled coil would extend out from the pneumococcal
surface and would therefore be exposed and available to be bound
by antibodies in vivo. These two characteristics – immunogenicity
and exposure on the surface – are critical for a successful vaccine
antigen. It is interesting to note that another leading protein
vaccine candidate for the pneumococcus, PspA, also contains
coiled-coil motifs that are thought to be immunogenic and exposed
[28]. This common structural feature may be necessary to allow
these proteins to protrude through the capsule layer and access the
extracellular milieu in order to interact with host surfaces and/or
carry out their respective functions. However, this could also be an
‘Achilles heel’ that could be targeted by vaccination. There is some
apprehension that antibodies against the coiled-coil regions of
PspA could be cross-reactive with cardiac myosin, which also
forms a coiled-coil structure. However, such concerns can be
allayed somewhat by the fact that there are no known associations
between pneumococcal infections and autoimmune conditions,
even though the majority of adults have significant levels of
antibodies to PspA in their serum [29].
The data from the initial ELISAs were largely consistent with
the antibody titre data from the D39 and P9 sepsis model
experiments (see Tables 3 and 4). These both showed that mice
immunised with the PhtD adjunct developed a very high titre of
IgG, showing that this region is indeed highly immunogenic.
Protective immunity elicited by immunisation with
truncated proteins in D39 sepsis model
Immunisation with the PhtD adjunct elicited a significant
increase in median survival time of mice after challenge with D39,
whereas immunisation with the full length protein did not. Since it
contains all potential epitopes, it might be expected that the full
length protein would either be equal or superior to any truncated
forms in terms of vaccine efficacy, but this was not the case. This
result may be due to an effect of the dose of protein given. In this
experiment, mice were immunised with 10 mg of each protein per
dose, which implies that the dose of the adjunct proteins was
approximately four-fold greater in molar terms than that of the full
length proteins, due to the difference in molecular weight of the
full length and adjunct proteins. Consistent with the ELISA data
showing that the PhtD adjunct is immunodominant (a high
proportion of antibodies in the polyclonal antiserum generated
against the full length protein could bind to the PhtD adjunct), the
titre of pooled mouse serum from the PhtD adjunct group against
the adjunct protein was much greater than that of the PhtD group
against the full length protein. This difference in the level of
antibody in the mice could account for the increase in survival
time, since antibodies against pneumococcal proteins are known to
be a major correlate of protective immunity against invasive
disease [30,31].
Failure to elicit protective immunity in D39 colonisation
and P9 sepsis models
Disappointingly, almost no protective effects were seen in either
the D39 colonisation or the P9 sepsis models. The result of the
former is particularly surprising given that Godfroid et al. [16]
showed that immunisation with PhtD decreases the bacterial load
in the nasopharynx. The two experiments used the same adjuvant,
immunisation schedule and challenge strain (D39). There were
differences in the challenge dose (76104 in the published study
versus 6.56106 here) and strain of mice (BALC/c versus CD1)
used. BALB/c mice have been shown to be more resistant to
pneumococcal infections than several other mouse strains, and this
is associated with a more vigorous immune response [32].
However, CD1 mice, which are outbred, were not tested in that
study. Recently, another pertinent study has found that significant
protection against colonisation is induced by immunisation with
either PhtD or PhtD using strain TIGR4 in C57BL/6 mice [33].
The differences in challenge doses and strains of mice and/or
pneumococci used in the two previous studies and this report may
be responsible for the differences in efficacy of vaccination with
PhtD observed.
In the P9 sepsis model, PhtD N1 was the only PhtD derivative
that significantly increased survival time compared to the alum
control group. This confirms that critical immunogenic epitopes
are not located at the N-terminus. However, it cannot be
concluded that the PhtD N1 protein was actually more able to
induce protective immunity than the full length protein or any
truncated derivatives, since there were no statistically significant
differences in survival time between the N1 group and any of these
other groups. Neither full-length PhtD nor any of the other
truncated derivatives conferred significant protective effects
compared to the alum control group. This is surprising, given
that substantial IgG titres were generated against PhtD and its
truncated derivatives, and flow cytometry showed that PhtD on
the surface of P9 was highly accessible to these antibodies. It is
possible that Pht proteins make a lesser contribution to the
pathogenicity of P9 than they do to other strains, which would
mean that blockade of their function via antibody binding would
have a lesser effect on the course of disease.
When combined with the pneumolysoid PdT, neither full-length
PhtD nor the PhtD adjunct increased the median survival time
compared to when PdT was given alone. A similar absence of
additive protection has previously been reported for combinations
of PhtB and PhtE with PspA and another pneumolysin toxoid PdB
[9]. Outside of this report, there is a dearth of reports examining
immunisation with combinations of Pht and other pneumococcal
antigens. In light of the results found here, it will be important to
examine this in future studies, since the lack of additive protection
could make Pht proteins significantly less attractive as vaccine
candidates.
This study has identified a potentially important region in PhtD
that is highly immunogenic and surface exposed, but has also cast
doubt on the efficacy of PhtD as a vaccine candidate relative to
other antigens. If PhtD is to be investigated further as a vaccine
candidate, the adjunct region should be considered as a
replacement for the full length protein, given its potential to elicit
superior antibody responses and protective immunity.
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